ARA-290

ARA-290 is an investigational peptide derived from the helix B region of erythropoietin (EPO). Also known as cibinetide, ARA-290 has been studied extensively in experimental research involving tissue protection, inflammatory signalling, neuropathic pain mechanisms, neurobiology, and cellular repair pathways.

Unlike erythropoietin itself, ARA-290 was developed to investigate the biological activity associated with the tissue-protective properties of the EPO molecule without being primarily focused on stimulating red blood cell production.

Research involving ARA-290 has explored interactions between the peptide and the innate repair receptor (IRR), a proposed receptor complex associated with tissue-protective and anti-inflammatory signalling. Preclinical and early clinical research has investigated ARA-290 in areas including nerve injury, metabolic disorders, inflammation, and tissue repair.

ARA-290 is an investigational research compound and should not be presented as an approved medication or established treatment. It is intended for legitimate laboratory research and is not intended for human consumption, self-administration, or veterinary use.

What Is ARA-290?

ARA-290 is a small synthetic peptide derived from the helix B region of erythropoietin.

The compound has attracted scientific interest because researchers identified biological effects associated with EPO that appear to be distinct from its classical role in erythropoiesis.

This led to research into shorter EPO-derived peptides that could potentially reproduce tissue-protective signalling without relying on the traditional erythropoietic pathway.

ARA-290 became one of the best-known experimental compounds developed from this research programme.

ARA-290 and Erythropoietin

Erythropoietin is a naturally occurring glycoprotein hormone best known for regulating red blood-cell production.

Research into EPO subsequently identified additional biological activities involving tissue protection, inflammation, vascular biology, and cellular survival.

ARA-290 was developed from the helix B region of EPO, allowing researchers to investigate these non-erythropoietic pathways separately from the classical EPO receptor system.

This distinction is important:

ARA-290 is not the same molecule as erythropoietin.

It is a smaller synthetic peptide derived from a specific region of EPO.

ARA-290 Research

ARA-290 has been investigated across several areas of experimental biology, including:

• Neurobiology
• Neuropathic pain research
• Inflammatory signalling
• Tissue-protection mechanisms
• Cellular repair
• Metabolic research
• Nerve-injury models
• Vascular biology
• Mitochondrial research
• Immune signalling
• Cytoprotection

These areas describe scientific research rather than established therapeutic indications.

ARA-290 and the Innate Repair Receptor

One of the most important concepts in ARA-290 research is the proposed innate repair receptor.

Researchers have investigated whether ARA-290 and related EPO-derived peptides interact with a receptor complex distinct from the classical erythropoietin receptor.

The proposed innate repair receptor has been studied in relation to tissue-protective signalling, inflammatory regulation, cellular survival, and repair mechanisms.

This research has helped establish ARA-290 as a useful experimental tool for investigating how EPO-derived peptides may influence tissue biology independently of erythropoiesis.

ARA-290 and Neurobiology

ARA-290 has received considerable attention in experimental neuroscience.

Research has examined the peptide in models involving peripheral nerve injury, neuropathic pain, neuronal stress, and neuroinflammatory signalling.

The scientific interest comes partly from the possibility that tissue-protective signalling may influence neuronal and supporting-cell responses following injury or metabolic stress.

However, experimental findings should not be interpreted as evidence that ARA-290 is an established treatment for neurological disease or neuropathic pain.

ARA-290 and Neuropathic Pain Research

Neuropathic pain is associated with abnormal signalling within the nervous system following nerve damage or dysfunction.

ARA-290 has been investigated in experimental models designed to understand mechanisms associated with neuropathic pain and nerve-related inflammation.

Early human research has also explored ARA-290 in selected populations, contributing to scientific interest in the compound.

Nevertheless, clinical evidence remains limited, and additional controlled research is necessary to establish its safety, pharmacology, and therapeutic effectiveness.

ARA-290 and Inflammation Research

Inflammation is a complex biological response involving immune cells, cytokines, vascular signalling, and tissue responses.

ARA-290 research has investigated how EPO-derived tissue-protective signalling may influence inflammatory pathways without producing the classical erythropoietic effects associated with full-length EPO.

Researchers may therefore use ARA-290 in experimental systems investigating relationships between tissue injury, inflammation, cellular stress, and repair.

ARA-290 and Tissue Protection

A major research interest surrounding ARA-290 is cytoprotection, or the mechanisms through which cells respond to potentially damaging conditions.

Experimental studies have investigated EPO-derived peptides in relation to cellular survival, tissue injury, inflammatory responses, and repair processes.

These studies have helped researchers explore whether signalling pathways associated with EPO can be separated from its effects on red blood-cell production.

ARA-290 and Metabolic Research

ARA-290 has also been investigated in metabolic research.

Experimental and early clinical studies have examined the compound in contexts involving metabolic dysfunction, nerve biology, inflammation, and tissue responses.

These studies are relevant to researchers investigating interactions between metabolism, inflammation, and cellular protection.

However, research findings do not establish ARA-290 as an approved metabolic treatment.

ARA-290 and Nerve Research

Peripheral nerves are particularly sensitive to metabolic and inflammatory changes.

Researchers have investigated ARA-290 in experimental models involving nerve injury and peripheral nerve dysfunction.

Areas of interest include:

• Neuronal signalling
• Neuroinflammation
• Nerve regeneration mechanisms
• Schwann-cell biology
• Cellular stress
• Tissue-protective signalling

This makes ARA-290 relevant to laboratories investigating the molecular biology of peripheral nerves and tissue repair.

ARA-290 and Mitochondrial Research

Mitochondria play a central role in cellular energy production and stress responses.

Because ARA-290 research includes cellular protection and metabolic signalling, researchers have investigated relationships between EPO-derived peptides, mitochondrial function, oxidative stress, and cellular survival.

These mechanisms remain an active area of scientific investigation.

ARA-290 Product Information

Product: ARA-290
Alternative name: Cibinetide
Origin: Derived from the helix B region of erythropoietin
Compound type: Synthetic peptide
Research areas: Neurobiology, tissue protection, inflammatory signalling, nerve research and metabolic biology
Intended use: Laboratory research only
Human use: Not for human use
Veterinary use: Not for veterinary use

Researchers should refer to the current product documentation for exact information regarding peptide identity, purity, analytical testing, batch information, storage requirements, and handling procedures.

ARA-290 vs EPO

ARA-290 and erythropoietin should not be treated as interchangeable compounds.

Erythropoietin (EPO) is a naturally occurring glycoprotein hormone with a well-established role in red-blood-cell production.

ARA-290 is a much smaller synthetic peptide derived from the helix B region of EPO and is researched primarily for non-erythropoietic tissue-protective signalling.

This distinction is important when interpreting scientific literature because findings involving full-length EPO cannot automatically be attributed to ARA-290.

ARA-290 vs BPC-157

ARA-290 and BPC-157 are both investigational peptides, but they have different origins and research profiles.

ARA-290 is derived from the helix B region of erythropoietin and has been investigated particularly in relation to tissue-protective signalling, nerve biology, and inflammation.

BPC-157 is a synthetic pentadecapeptide investigated in areas including gastrointestinal, vascular, musculoskeletal, and cellular research.

They should therefore be considered distinct research compounds rather than interchangeable peptides.

ARA-290 Research Documentation

For laboratory applications, appropriate analytical documentation is important.

Where available, researchers should review:

• Certificate of Analysis (CoA)
• Batch or lot number
• Peptide identity
• Sequence information
• Purity analysis
• Analytical testing
• Molecular-weight information
• Storage requirements
• Handling instructions

Batch-specific documentation provides researchers with a clearer record of the material used during an experiment.

Frequently Asked Questions

What is ARA-290?

ARA-290 is an investigational synthetic peptide derived from the helix B region of erythropoietin. It has been studied in tissue-protection, neurobiology, inflammatory signalling, and nerve-research models.

What is another name for ARA-290?

ARA-290 is also known as cibinetide.

Is ARA-290 the same as erythropoietin?

No. ARA-290 is a short peptide derived from a region of erythropoietin, while EPO itself is a much larger glycoprotein hormone.

Why is ARA-290 researched?

Researchers investigate ARA-290 in areas including tissue protection, neurobiology, neuropathic pain mechanisms, inflammatory signalling, nerve biology, metabolic research, and cellular repair.

What is the innate repair receptor?

The innate repair receptor is a proposed receptor complex studied in connection with tissue-protective and anti-inflammatory signalling associated with EPO-derived peptides.

Is ARA-290 a peptide?

Yes. ARA-290 is a synthetic peptide derived from the helix B region of erythropoietin.

Is ARA-290 the same as BPC-157?

No. They are structurally different investigational peptides with different biological origins and research applications.

Is ARA-290 FDA approved?

ARA-290 should not be represented as an FDA-approved medication. It remains an investigational compound.

Does ARA-290 have human research?

Yes. ARA-290 has been investigated in early human studies as well as extensive preclinical research. However, the available evidence should not be represented as establishing an approved clinical treatment.

Is ARA-290 intended for human use?

Research-grade ARA-290 should be supplied for legitimate laboratory research and should not be marketed for human consumption or self-administration.

Research Disclaimer

This information is provided for educational and legitimate laboratory research purposes. It does not constitute medical advice, treatment guidance, or a recommendation for human use.

ARA-290 research material is not intended for human consumption, self-administration, or veterinary use. Researchers are responsible for complying with applicable laws, regulations, institutional requirements, and laboratory safety procedures.

ARA-290 Research Peptide

ARA-290 represents an interesting area of peptide research because it sits at the intersection of erythropoietin biology, tissue protection, inflammation, neurobiology, and cellular repair.

Its development reflects a broader scientific effort to understand whether specific regions of larger biological molecules can produce distinct signalling effects.

For laboratories investigating ARA-290, the most important considerations are accurate compound identification, reliable analytical documentation, appropriate handling, and careful interpretation of preclinical and clinical evidence.